Anti-Parkinson's disease drugs and pharmacogenetic considerations (Q38097097)

28 August 2017

title

Anti-Parkinson's disease drugs and pharmacogenetic considerations (English)

1 reference

28 August 2017

José A G Agúndez

1 reference

28 August 2017

Elena García-Martín

1 reference

28 August 2017

Elena García-Martín

1 reference

28 August 2017

Hortensia Alonso-Navarro

1 reference

28 August 2017

Félix Javier Jiménez-Jiménez

1 reference

28 August 2017

language of work or name

English

0 references

publication date

9 April 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

28 August 2017

published in

1 reference

28 August 2017

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

859-874

1 reference

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Biperiden effects and plasma levels in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Oxidative polymorphism of debrisoquine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

A revision of the metabolic disposition of amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Increase of Cerebral Catecholamines caused by 3,4-Dihydroxyphenylalanine after Inhibition of Peripheral Decarboxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Carbidopa in Parkinson disease and in nausea and vomiting of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Variable absorption of carbidopa affects both peripheral and central levodopa metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacokinetics of the decarboxylase inhibitor benserazide in man; its tissue distribution in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

The effect of tolcapone on the pharmacokinetics of benserazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

A review of the receptor-binding and pharmacokinetic properties of dopamine agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Cabergoline plasma concentration is increased during concomitant treatment with itraconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Clinical pharmacokinetics of ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Steady-state pharmacokinetic properties of pramipexole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Subcutaneously administered apomorphine: pharmacokinetics and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Dopamine receptor D3 (DRD3) genotype and allelic variants and risk for essential tremor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Quantitative analysis of selegiline and three metabolites (N-desmethylselegiline, methamphetamine, and amphetamine) in human plasma by high-performance liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Clinical Pharmacokinetics and Pharmacodynamics of Selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Clinical advantages of COMT inhibition with entacapone - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Pharmacogenomics in drug induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Utility of tolcapone in fluctuating Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Idiosyncratic drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Unraveling ambiguous NAT2 genotyping data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

Phenomics: the next challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

The Relationship between COMT Genotype and the Clinical Effectiveness of Tolcapone, a COMT Inhibitor, in Patients with Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.789018

10.1517/17425255.2013.789018

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference